Clinical trials: Treatment-Resistant Depression
Treatment Resistant Depression, Ketamine
ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression
To determine if an high intensity ketamine with ECT rescue (HIKER) approach for treatment resistant depression will: 1) reduce patient suffering by hastening disease remission, 2) have fewer side effects, 3) reduce the need for…
- Trial name
- NCT03272698
- Testing
- Ketamine, ECT
- Where
- Canada
- Volunteers
- 62 people
- Sponsor
- University of Saskatchewan
Depression
Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication
This study will examine how brain activity is affected by antidepressant treatment and how changes in brain activity relate to treatment response in people with depression.
- Trial name
- NCT00375843
- Testing
- Escitalopram, Sertraline
- Where
- 3 sites in United States
- Volunteers
- 118 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression (TRD)
Treatment Resistant Depression and Vagus Nerve Stimulation
Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments.
- Trial name
- DepVNS (NCT05952674)
- Testing
- Vagus Nerve Stimulation (VNS), Best Medical Treatment
- Where
- 24 sites in France
- Volunteers
- 166 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Treatment-resistant Depression
Psychosocial Characteristics and Non-pharmacological Intervention of Patients With Treatment-resistant Depression
Pharmacotherapy and psychotherapy, effective management strategies for treatment-resistant depression are limited and yet to be developed.
- Trial name
- NCT03329391
- Testing
- Nurse-led cognitive-behavioral-based group intervention
- Where
- Taiwan
- Volunteers
- 46 people
- Sponsor
- National Taiwan University Hospital
Treatment-Resistant Depression
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
Approximately one third of individuals with Major Depressive Disorder (MDD) are considered treatment-resistant, subject to severe disability and risk of suicide, and exhibit symptoms anchored in abnormalities of Research Domain…
- Trial name
- LIFU CANVAS (NCT07166289)
- Testing
- Low-intensity focused ultrasound
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Bipolar II Depression
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder
This study is a 12-week (in addition to up to 30 days of screening) randomized, double-blind, placebo-controlled, parallel-group trial.
- Trial name
- PAT-BD-01 (NCT06943573)
- Testing
- psilocybin (25 mg), psilocybin 1mg micro-dose
- Where
- 3 sites in Canada
- Volunteers
- 90 people
- Sponsor
- Lakshmi N Yatham
Treatment-Resistant Depression
Focal Electrically Administered Seizure Therapy for the Treatment of Depression
The purpose of this study is to determine the efficacy and any possible side effects of focal electrically administered seizure therapy (FEAST) as a treatment intervention for patients with recurrent and treatment resistant…
- Trial name
- FEAST (NCT02462551)
- Testing
- Focal Electrically Administered Seizure Therapy
- Where
- Lebanon
- Volunteers
- 30 people
- Sponsor
- Ziad Nahas
Treatment Resistant Depression (TRD)
Neuronavigated aiTBS for TRD
The purpose of this study is to confirm the efficacy of two recently introduced repetitive transcranial magnetic stimulation (rTMS) interventions - accelerated intermittent theta-burst stimulation (aiTBS) and individualized…
- Trial name
- NCT07329153
- Testing
- aiTBS
- Where
- 3 sites in United States
- Volunteers
- 247 people
- Sponsor
- University of Texas Southwestern Medical Center
Treatment Resistant Depressive Disorder
Efficacy and Safety of DBS in Patients With Treatment-Resistant Depression
The habenula (Hb) is an ancient structure, located at the center of the dorsal diencephalic conduction system, a pathway involved in linking forebrain to midbrain regions.
- Trial name
- NCT03667872
- Testing
- Bilateral implantation of DBS system to Habeluna
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Depression
taVNS or TMS or Both for Depression
The purpose of the research is to test out a combined treatment for depression where the investigators stimulate a nerve in the ear while at the same time stimulate the brain with magnets.
- Trial name
- NCT05725239
- Testing
- Vagus Nerve Stimulation, Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Medical University of South Carolina
Suicidal Ideation, Treatment-resistant Depression
Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI
This is a prospective clinical trial to confirm the effectiveness of bilateral accelerated theta burst stimulation (aTBS) on suicidal ideation (SI), while exploring cortical inhibition measures in this treatment paradigm.
- Trial name
- COMBAT-SI (NCT05377177)
- Testing
- Accelerated Theta Burst Stimulation
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of California, San Diego
Depression
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued duloxetine in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01309945
- Testing
- Duloxetine, BMS-820836
- Where
- 84 sites in United States, Canada and 4 more
- Volunteers
- 889 people
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD)
Comparison of Efficacy of Minocyclin and Celecoxib as Adjunctive Treatment in Treatment Resistant Cases of Major Depressive Disorder
This randomized controlled study was conducted to compare the effectiveness of minocycline and celecoxib as add-on treatments in patients with treatment-resistant major depressive disorder.
- Trial name
- NCT07804979
- Testing
- Minocycline, Celecoxib
- Where
- Pakistan
- Volunteers
- 78 people
- Sponsor
- Lahore General Hospital
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression
The RTMSECT2 study was design to compare the application of electroconvulsive therapy augmented by transcranial magnetic stimulation.
- Trial name
- RMTSECT2 (NCT07324070)
- Testing
- Electroconvulsive therapy, Transcranial Magnetic Stimulation
- Where
- Czechia
- Volunteers
- 50 people
- Sponsor
- Charles University, Czech Republic
Major Depressive Disorder, Treatment Resistant
Nuedexta in Treatment-Resistant Major Depression
There is an urgent need, therefore, to identify well-tolerated, orally available compounds that target the NMDA receptor as a novel treatment approach for TRD.
- Trial name
- NCT01882829
- Testing
- dextromethorphan/quinidine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- James Murrough
Schizophrenia, Diabetes
Medication Reviews in Severe Mental Illness
This study aims to investigate the potential beneficial effects of a medication review by a clinical pharmacologist on patients with coexisting severe mental illness and diabetes.
- Conditions
- Schizophrenia, Diabetes, Metabolic Syndrome, Severe Mental Disorder
- Trial name
- NCT05243160
- Testing
- medication review
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Psychiatric Research Unit, Region Zealand, Denmark
Major Depressive Disorder, Major Depressive Episode
Glabellar Botulinum Toxin Injections for the Treatment of Geriatric Depression
The effectiveness of glabellar injection of botulinum toxin type A (BTA) in treating depression has not yet been investigated in elderly patients.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Treatment Resistant Depression
- Trial name
- BOTDEP (NCT03833063)
- Testing
- botulinum toxin A
- Sponsor
- Helse Stavanger HF
Major Depressive Disorder, Treatment Resistant Depression
Open-Label Safety Study of AXS-05 in Subjects With Depression
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Trial name
- NCT04039022
- Testing
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Where
- 51 sites in United States
- Volunteers
- 876 people
- Sponsor
- Axsome Therapeutics, Inc.
Depression, Depressive Disorder
Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression
Many patients with depression do not respond well to medication and are diagnosed with treatment refractory depression (TRD). Sometimes medications don't work because an individual metabolizes the drugs in an atypical manner (too…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major, Depression, Bipolar
- Trial name
- NCT04469322
- Testing
- Mental Health DNA Insight Test (Pathway Genomics)
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- San Diego Veterans Healthcare System
Depression - Major Depressive Disorder, Depression Disorder
Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression
The primary aim of this study is to evaluate the efficacy and tolerability of a combined Virtual Reality (VR)-based mindfulness intervention and pharmacological treatment compared with pharmacological treatment alone in reducing…
- Conditions
- Depression - Major Depressive Disorder, Depression Disorder, Depression Chronic, Treatment-Resistant Major Depressive Disorder
- Trial name
- NCT07422519
- Testing
- Virtual-Reality-based mindfulness intervention, Esketamine Treatment as Usual (ESK)
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute